Market Newsdesk

SAN FRANCISCO, July 7, 2026 /PRNewswire/ — National shareholder rights firm Hagens Berman Sobol Shapiro (HBSS) has launched an investigation into Medline Inc. (NASDAQ: MDLN) focusing on whether the company may have misled investors regarding the adequacy of its manufacturing quality controls and compliance with FDA safety standards.

SUBMIT YOUR MDLN INVESTMENT LOSSES TO HBSS NOW

The firm is looking into whether Medline concealed systemic lapses in its contamination protocols—specifically failures to investigate microbial incidents and batch discrepancies—that prompted regulatory scrutiny and triggered a significant decline in the company’s share price.

Visit:
www.hbsslaw.com/investor-fraud/mdln

Contact the Firm Now:
[email protected]

                                       844-916-0895

Medline Inc. (MDLN) Investigation:

Since Medline went public in December 2025, it has assured investors that “[w]e are committed to delivering products of the highest standard, which is reflected by our robust quality team of over 2,400 employees[]” and “[t]heir expertise ensures that every product bearing the Medline brand meets both our rigorous quality standards and our customers’ expectations[.]”

The effectiveness of the company’s quality team first came into question on June 2, 2026, when the FDA published its May 28 warning letter addressed to CEO Boyle. The FDA recited specific CGMP violations and said “your drug products are adulterated[.]”

The FDA highlighted the following deficiencies:

• “Between June 2, 2023 and August 27, 2025, your firm isolated objectionable microorganisms […] from finished drug product samples on approximately nine occasions[;]”
• “You also recovered [the objectionable microorganisms] in at least five samples taken from your manufacturing environment since January 2025[;]”
• “You failed to adequately investigate and implement corrective actions and preventative actions (CAPA) to determine root causes and prevent recurrence of these repeated contamination incidents[;]” and
• “This issue was cited on the previous Form FDA 483 issued to your firm in January 2025 and subsequently discussed during the most recent regulatory meeting held with your firm in May 2025.”

Investors also learned for the first time the next day that, as a result of the quality problems, Medline had shut down certain problematic facilities last October.

The market’s significantly negative reaction to these revelations erased about $2.2 billion from Medline’s market capitalization.

“We’re focused on whether Medline concealed from investors the serious concerns raised by the FDA,”  said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

If you invested in Medline and have substantial losses, or have knowledge that may assist the firm’s investigation, submit your losses now »

If you’d like more information and answers to other frequently asked questions about the Medline case and the firm’s investigation, read more »

Whistleblowers: Persons with non-public information regarding Medline should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

View original content to download multimedia:https://www.prnewswire.com/news-releases/mdln-alert-hbss-probes-medline-mdln-after-reports-reveal-undisclosed-manufacturing-violations-and-failed-contamination-investigations-302820094.html

SOURCE Hagens Berman Sobol Shapiro LLP

Lead Plaintiff Deadline Remains July 17, 2026

SAN FRANCISCO, July 7, 2026 /PRNewswire/ — Hagens Berman, a national shareholder rights firm, alerts investors in Commvault Systems, Inc. (NASDAQ: CVLT) that a newly filed securities class action lawsuit has expanded the alleged class period. The lawsuit now covers investors who purchased or otherwise acquired Commvault securities between January 28, 2025, and January 26, 2026, inclusive.

Hagens Berman is investigating the claims pled in the pending litigation and encourages Commvault investors who suffered substantial losses to submit your losses now.

Expanded Alleged Class Period: Jan. 28, 2025 – Jan. 26, 2026
Lead Plaintiff Deadline: July 17, 2026
Visit:www.hbsslaw.com/investor-fraud/cvlt
Contact the Firm Now: [email protected]
                                       844-916-0895

Expanded Scope of Allegations

The new suit, City of Fort Lauderdale Police and Firefighters’ Retirement System v. Commvault Systems, Inc., et al., extends the start of the allegedfraud period from April 29, 2025, back to January 28, 2025. This expansion captures a broader range of investor activity and expands the claims brought against the company and its senior executives regarding their business disclosures.

Focus of CVLT Securities Class Action Litigation:

The litigation alleges that Defendants misrepresented and failed to disclose that:

• Commvault’s competitive positioning was materially weaker than Defendants had represented to investors;
• Due to the undisclosed increase in competition, Commvault was forced to make significant concessions on price and contract duration for its software licenses;
• As these concessions became unsustainable, SaaS became a larger portion of the Company’s sales mix;
• The increasing mix of SaaS sales, which carry shorter term durations and lower ASPs, negatively impacted the Company’s margin and NNARR; and
• As a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

The truth allegedly emerged before markets opened on January 27, 2026, when Commvault announced its third-quarter fiscal year 20261 financial results. Commvault disclosed NNARR in constant currency of $39 million, missing analysts’ expectations of approximately $45 million. Chief Accounting Officer Danielle Abrahamsen (“CAO Abrahamsen”) revealed that the mix of SaaS deals increased to “70%” during the quarter and highlighted that “landing these customers at a 2 to 3x smaller ASP than software . . . does have a significant impact on ARR.”

On this news, the price of Commvault common stock fell $40.23 per share, or about 31%, to close at a price of $89.13 per share on January 27, 2026.

HBSS Investigation

“We continue to investigate whether Commvault misled investors about its operational performance and financial reporting during the alleged expanded class period, as the new complaint contends” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation of the pending claims.

If you invested in Commvault and have substantial losses, or have knowledge that will assist the firm’s investigation, submit your losses now.

If you’d like more information and answers to frequently asked questions about the Commvault case and the firm’s investigation, read more »

Whistleblowers: Persons with non-public information regarding Commvault should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cvlt-10-day-deadline-alert-hbss-alerts-commvault-cvlt-investors-to-expanded-class-period-in-securities-class-action-302820095.html

SOURCE Hagens Berman Sobol Shapiro LLP

SAN FRANCISCO, July 7, 2026 /PRNewswire/ — Black Rock Coffee Bar, Inc. (NASDAQ: BRCB) faces a securities class action lawsuit related to disclosures the company made to investors within its initial public offering documents whereby it issued about 16.9 million shares to investors at $20 per share. The lawsuit seeks to represent investors who purchased or otherwise acquired Black Rock common stock in and/or traceable to the company’s September 2025 IPO.

By the time the lawsuit was filed on June 18, 2026, Black Rock Coffee shares had steadily declined to $7.72, or over 61% below the IPO price.

The recent revelations about Black Rock Coffee’s slowing growth metrics and severe share price decline support national shareholder rights firm Hagens Berman’s investigation into legal claims that Black Rock and its co-defendants violated the federal securities laws.

The firm encourages Black Rock investors who suffered substantial losses to submit your losses now.

Lead Plaintiff Deadline: Aug. 17, 2026
Visit:www.hbsslaw.com/investor-fraud/brcb
Contact the Firm Now: [email protected]
                                       844-916-0895

Black Rock Coffee Bar, Inc. (BRCB) Securities Class Action:

Black Rock characterizes itself as a “high-growth operator of guest-centric, drive-thru coffee bars offering premium caffeinated beverages and an elevated in-store experience crafted by our engaging baristas.”

Within the company’s offering documents, it touted an aggressive growth story, stating that it has opened and plans to open additional stores in markets where it has little or no operating experience. To support its business plan, Black Rock cited metrics such as increasing store count, increasing store revenue, increasing same store sales (“SSS”) growth, increasing income from operations, and others.

The complaint alleges that Black Rock’s IPO documents misled investors because they did not disclose critical information to investors, such as new store openings were leading to a cannibalization of its existing services and revenue. In addition, the complaint alleges that Black Rock overstated the manner in which its expansion strategy was tailored to avoid situations where a portion of volume from existing stores shifts to newer stores in closer proximity to customers (“sales transfer”) that negatively affected revenue growth.

On May 12, 2026, Black Rock reported its Q1 2026 financial results. The company reported a large sequential decrease (-44%) in SSS growth – down from 9.3% to 5.2%. Of critical importance, during the earnings call that day, management revealed that the sales transfer phenomenon (i.e. cannibalization) created a 160-basis point headwind to SSS growth, raising doubts about the efficacy of Black Rock’s expansion strategy.

The company also reported opening nine new stores during the quarter, yet sequentially added just $1.9 million of revenues representing a slowing sequential growth rate to about 3.5%.

In response, the market drove the price of Black Rock shares down $3.32 (-30%) on May 13, 2026.

“We’re focused on whether Black Rock Coffee’s IPO documents were negligently prepared for failing to disclose adverse facts about the sales transfer phenomenon embedded in the company’s growth strategy,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

If you invested in Black Rock Coffee and have substantial losses, or have knowledge that will assist the firm’s investigation, submit your losses now.

If you’d like more information and answers to other frequently asked questions about the Black Rock Coffee case and the firm’s investigation, read more.

Whistleblowers: Persons with non-public information regarding Black Rock Coffee should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/black-rock-coffee-bar-inc-brcb-faces-securities-class-action-related-to-ipo-disclosures-regarding-adverse-impact-of-sales-transfer-phenomenon–hbss-302820089.html

SOURCE Hagens Berman Sobol Shapiro LLP

SAN FRANCISCO, July 7, 2026 /PRNewswire/ — Embecta Corp. (NASDAQ: EMBC) faces a securities class action lawsuit, which seeks to represent investors who purchased or acquired Embecta common stock between November 25, 2025 and May 4, 2026. The lawsuit follows the company’s disastrous Q2 2026 earnings report, apparently at odds with prior narrative, which triggered a massive selloff in the stock and analysts’ questions.

These developments have prompted national shareholder rights firm Hagens Berman to open an investigation into claims that Embecta violated the federal securities laws.

The firm encourages Embecta investors who suffered substantial losses to submit your losses now.

Class Period: Nov. 25, 2025 – May 4, 2026
Lead Plaintiff Deadline: Aug. 17, 2026
Visit:www.hbsslaw.com/investor-fraud/embc
Contact the Firm Now: [email protected]
                                         844-916-0895

Embecta Corp. (EMBC) Securities Class Action:

Embecta is a global medical device company whose core business product is pen needles – sterile, single-use, medical devices, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. In the past, pen needle revenues have comprised over 70% of the company’s total revenues.

The litigation’s primary focus is on the propriety of Embecta’s Class Period repeated assurances that “insulin pens have been stable […] showing the underlying resilience and the durability of that portfolio[]” and “our pen needle business is incredibly resolute.” This narrative formed the basis for the company’s February 5, 2026 guidance reiterating 2026 adjusted EPS of $2.80 – $3.00. The company also touted maintenance of its dividend within its capital allocation plans as a return of capital to shareholders.

The complaint alleges the company’s assurances and guidance were misleading when given because Embecta knew or recklessly disregarded that weaknesses in the pen needle market was likely to significantly disrupt the company’s annual guidance and Q2 results.

On May 5, 2026, investors’ expectations vanished. That day, Embecta reported Q2 2026 adjusted EPS of $0.27, a staggering sequential and year-over-year decline of about 61%. In contrast to the company’s assurances of stability, resilience, and durability, Embecta’s pen needles revenues also suffered massive sequential and year-over-year declines. Of additional concern, Embecta slashed its 2026 adjusted EPS guidance to $1.55 – $1.75, or down roughly 43% at the mid-point, and reduced its dividend by 93% to just $0.01.

In response, the market sent the price of Embecta shares tumbling, with one prominent analyst who downgraded the company highlighting Embecta management’s “need to rebuild investor credibility on commercial execution and the profitability outlook.”

“Our investigation is focused the extent to which and when Embecta and its management knew about pen needle and U.S. business revenue headwinds, and whether they were sufficiently transparent about those risks,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

If you invested in Embecta and have substantial losses, or have knowledge that will assist the firm’s investigation, submit your losses now »

If you’d like more information and answers to other frequently asked questions about the Embecta case and the firm’s investigation, read more »

Whistleblowers: Persons with non-public information regarding Embecta should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

View original content to download multimedia:https://www.prnewswire.com/news-releases/embecta-corp-embc-faces-securities-class-action-over-alleged-concealed-material-risks-to-pen-needle-revenue-hbss-302820081.html

SOURCE Hagens Berman Sobol Shapiro LLP

SAN FRANCISCO, July 7, 2026 /PRNewswire/ — Erasca, Inc. (NASDAQ: ERAS) faces a securities class action after the stock tanked $9.25 (-48%) on news that Revolution Medicines (RevMed) accused Erasca of patent infringement concerning Erasca’s pan-RAS molecular glue targeting solid tumors (ERAS-0015) and that a patient died one month after receiving ERAS-0015.

The lawsuit seeks to represent investors who purchased or otherwise acquired Erasca common stock between January 14, 2025 and April 26, 2026.

National shareholder rights law firm Hagens Berman is continuing its investigation into legal claims that Erasca violated the federal securities laws and urges Erasca investors who suffered significant losses to contact the firm now to discuss their rights.

Class Period: Jan. 14, 2025 – Apr. 26, 2026
Lead Plaintiff Deadline: Aug. 10, 2026
Visit:www.hbsslaw.com/investor-fraud/eras
Contact the Firm Now:[email protected]
                                        844-916-0895

Erasca, Inc. (ERAS) Securities Class Action:

Precision oncology company Erasca’s ERAS-0015 is the company’s investigational, oral, potentially “best-in-class” pan-RAS molecular glue under development to treat RAS-mutant solid tumors, including pancreatic ductal adenocarcinoma.

The complaint alleges that Erasca favorably compared the equivalence of its ERAS-0015 40 milligram dose cohort to RevMed’s RMC-6236 400 milligram dose cohort. In addition, as recently as March 12, 2026, Erasca allegedly assured investors of its ERAS-0015 intellectual property protection, and touted that its ERAS-0015 has “in-licensed one patent family from Joyo” that “includes one issued US patent, one pending US non-provisional patent application, one issued foreign patent, and thirteen pending foreign patent applications.”

The complaint alleges that Erasca misled the market because, unknown to investors, comparisons of ERAS-0015 to RMC-6236 were improper, exposed the company to intellectual property disputes, and as a result the company’s proffers about ERAS-0015 lacked a reasonable basis.

The truth allegedly emerged on April 27, 2026. That day, Erasca disclosed two important matters concerning the ERAS-0015 “best-in-class” narrative.

First, before the market opened, Erasca disclosed that it received a letter from RevMed’s legal counsel challenging the validity of Erasca’s intellectual property claims. RevMed contends Erasca obtained RevMed’s trade secrets through third-party misappropriation and deceptively compared the competing therapies.

Second, after the market closed, the company revealed that a patient being treated with ERAS-0015 suffered an adverse event, presented to the ER a month after receiving the treatment, and then died.

The market swiftly reacted to these disclosures, sending the price of Erasca shares down $9.25 (-48%) the next day and wiping out over $2.8 billion of Erasca’s market capitalization.

“We’re investigating whether Erasca may have intentionally misled investors about ERAS-0015’s safety profile and about a potential moat in its particular, highly competitive cancer treatment space,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

If you invested in Erasca and have substantial losses, or have knowledge that may assist the firm’s investigation, submit your losses now »

If you’d like more information and answers to other frequently asked questions about the Erasca case and the firm’s investigation, read more »

Whistleblowers: Persons with non-public information regarding Erasca should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

View original content to download multimedia:https://www.prnewswire.com/news-releases/erasca-eras-faces-securities-class-action-after-stock-declines-48-on-drug-safety-and-ip-concerns—hbss-302820077.html

SOURCE Hagens Berman Sobol Shapiro LLP

SAN FRANCISCO, July 7, 2026 /PRNewswire/ — Hagens Berman (HBSS), a securities litigation leader, is broadening its investigation into Verra Mobility Corp. (NASDAQ: VRRM) following the company’s disclosure of an abrupt leadership transition.  The news comes in the wake of a securities action suit stemming from the catastrophic loss of a major contract.

VRRM Investors Submit Your Losses Now to HBSS

Class Period: Feb. 24, 2026 – May 26, 2026
Lead Plaintiff Deadline: Aug. 4, 2026
Visit:www.hbsslaw.com/investor-fraud/vrrm
Contact the Firm Now: [email protected]
                                       844-916-0895

Leadership Vacuum

On June 1, 2026, Verra Mobility announced that long-time CEO David Roberts has abruptly stepped down, ending a 12-year tenure. This departure follows a volatile period for the company, initiated by the unexpected termination of a key contract with Avis Budget Group—a move that wiped out approximately $1.4 billion in shareholder value.

The Board of Directors has appointed former Chief Transformation and Legal Officer Jon Keyser as interim President and CEO while retaining a global search firm for a permanent replacement. Hagens Berman is investigating whether the departure is causally related to the allegations in the securities class action suit.

Verra Mobility Corporation (VRRM) Securities Class Action:

The complaint alleges Verra made false and misleading statements and did not disclose important information to investors about the true state of the Verra/Avis relationship and the likelihood of Verra receiving an Avis contract renewal.

The truth allegedly emerged on May 26, 2026, when Verra disclosed that it received a termination notice effective September 2026 from Avis regarding the companies’ contract, that it is taking immediate actions to cut costs, adapt operations, and reposition its business, and revised its 2026 outlook that significantly deviated from that given just twenty days prior.

Verra also revealed that it was reviewing the parties’ negotiations and handling of confidential information.

The news promptly sent the price of Verra shares 70% crashing lower on May 27, 2026, amputating $1.4 billion from the company’s market capitalization in a single day.

View our latest video summary of the allegations: youtu.be/FVEw5XACoGA

“Our investigation is focused on the extent to which and when Verra and its executives knew that renegotiations with Avis were far from constructive, as the May 26 surprise reveals,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

If you invested in Verra and have substantial losses, or have knowledge that will assist the firm’s investigation, submit your losses now.

If you’d like more information and answers to other frequently asked questions about the Verra case and the firm’s investigation, read more.

Whistleblowers: Persons with non-public information regarding Verra should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

View original content to download multimedia:https://www.prnewswire.com/news-releases/verra-mobility-corporation-nasdaq-vrrm-faces-securities-class-action-following-ceo-resignation-and-1-4-billion-shareholder-loss–hbss-302820080.html

SOURCE Hagens Berman Sobol Shapiro LLP

SAN FRANCISCO, July 7, 2026 /PRNewswire/ — On February 20, 2026, GRAIL, Inc. (NASDAQ: GRAL) shed over $2.2 billion of market capitalization after surprising investors with its NHS-Galleri Trial readout. The news caused huge investor losses and triggered a securities class action lawsuit seeking to represent investors who purchased or otherwise acquired shares of GRAIL common stock between May 13, 2025 and February 19, 2026.

National shareholder rights firm Hagens Berman is investigating the alleged claims that GRAIL and its co-defendant executives violated the federal securities laws and encourages GRAIL investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge about GRAIL’s NHS-Galleri Trial to contact the firm’s attorneys.

Class Period: May 13, 2025 – Feb. 19, 2026
Lead Plaintiff Deadline: Aug. 4, 2026
Visit:www.hbsslaw.com/investor-fraud/gral
Contact the Firm Now: [email protected]
                                         844-916-0895

GRAIL, Inc. (GRAL) Securities Class Action:

Commercial stage healthcare company GRAIL focuses on early cancer detection.

The litigation focuses on the propriety of GRAIL’s disclosures about the design of its NHS-Galleri trial (the “trial”) and the likelihood it would meet its primary endpoint – with three consecutive years of follow-up screening, the absolute reduction in the number of late stage (stages 3 and 4) cancer diagnoses.

During the Class Period, GRAIL expressed high confidence in the trial’s design and likely outcomes. They consistently stated that the three-year duration was specifically chosen to demonstrate a statistically significant reduction in combined stage 3 and 4 cancers.

The complaint alleges that GRAIL misled investors by creating the false impression that it possessed reliable information supportive of the probability of the trial achieving its primary endpoint. The complaint further alleges that GRAIL’s expressed optimism was unrealistic because, unknown to investors, the company had information suggesting that three years would be insufficient to support the trial’s achievement of the primary endpoint.

Investors learned the truth on February 19, 2026. That day, the defendants announced that the trial failed to achieve its primary endpoint. Of significant concern was the admission that “we probably should have allowed for a longer follow-up period.”

The market quickly reacted, sending the price of GRAIL shares down over 50% the next day.

“We’re focused on when GRAIL and its management knew that the need for a longer follow-up period diverged from the touted three-year duration,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation of the pending claims in the filed lawsuit.

If you invested in GRAIL and have substantial losses, or have knowledge that will assist the firm’s investigation, submit your losses now.

If you’d like more information and answers to other frequently asked questions about the GRAIL case and the firm’s investigation, read more.

Whistleblowers: Persons with non-public information regarding GRAIL should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-inc-gral-securities-class-action-filed-following-nhs-galleri-trial-failure-and-2-2-billion-market-cap-loss—-hbss-302820073.html

SOURCE Hagens Berman Sobol Shapiro LLP

SAN FRANCISCO, July 7, 2026 /PRNewswire/ — Hagens Berman (HBSS), a national leader in securities litigation, is actively investigating claims in a securities class action lawsuit against GeneDx Holdings (NASDAQ: WGS) and its executives, alleging defendants misled investors about the Fabric Genomics acquisition and synergy potential.

The suit follows a devastating 49% stock collapse on May 5, 2026 in response to the company’s disastrous Q1 2026 earnings report, including a $31.2 million impairment charge.

The firm urges GeneDx investors who suffered significant losses to contact the firm now.

Class Period: Apr. 16, 2025 – May 4, 2026
Lead Plaintiff Deadline: Aug. 3, 2026
Visit:www.hbsslaw.com/investor-fraud/wgs
Contact the Firm Now:[email protected]
                                        844-916-0895

The GeneDx Securities Class Action: The Fabrics Genomics Discrepancy

The complaint alleges that GeneDx falsely touted the acquisition of Fabric Genomics as a cornerstone of its efficiency and future profitability.

But on May 4, 2026, GeneDx reported dismal Q1 2026 financial results which included a massive tenfold increase in net loss compared to the prior year period. The Fabric Genomics business (which reported a $2.5 million revenue miss) was the largest contributor to the loss, as GeneDx recorded impairment charges related to the unit totaling $31.2 million, or about 94% of the cash paid for it just one year ago.

In addition, GeneDx’s ARR fell about $200 short, a surprise blamed on a huge, adverse change in product mix toward genome whose ARR was only half that of exome.  The company also said that exome and genome revenue growth would be “at least 20%,” substantially lower than it said as recently as February. As a result of GeneDx’s changed growth narrative, the company slashed 2026 revenue guidance by 12%.

Leadership Maneuver

In the wake of the stock price cratering, GeneDx recently appointed a new President, Mark Gardner. Hagens Berman is investigating whether this leadership change is causally related to alleged failures that preceded the May collapse.

“The complaint alleges that investors were sold a vision of technological synergy, only to be hit with a massive impairment charge,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.  “We’re investigating whether GeneDx’s leadership knew of a disconnect between their public projections and the internal reality of their acquisitions.”

If you invested in GeneDx and have substantial losses, or have knowledge that may assist the firm’s investigation, submit your losses now »

If you’d like more information and answers to other frequently asked questions about the GeneDx case and the firm’s investigation,  read more »

Whistleblowers: Persons with non-public information regarding GeneDx should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

View original content to download multimedia:https://www.prnewswire.com/news-releases/genedx-holdings-wgs-hit-with-securities-class-action-following-49-stock-collapse–hbss-302820072.html

SOURCE Hagens Berman Sobol Shapiro LLP

SAN FRANCISCO, July 7, 2026 /PRNewswire/ — Hagens Berman Sobol Shapiro LLP (HBSS), a leading national securities litigation firm, is investigating claims in a securities class action lawsuit against Sportradar Group (NASDAQ: SRAD) and its executives. The lawsuit is brought on behalf of investors who purchased or otherwise acquired Sportradar Class A ordinary shares between November 7, 2024 and April 21, 2026, and suffered financial losses.

The lawsuit follows the dramatic 22% single day collapse in SRAD stock price on April 22, 2026, triggered by damaging investigative reports from Muddy Waters Research and Callisto Research. These reports accused the company of deceiving investors about the legality of its core business model and true sources of its revenue.

Hagens Berman is actively investigating the claims that Sportradar violated federal securities laws. Investors who lost money on Sportradar stock (SRAD) are encouraged to submit your losses now to learn about their legal options and potential recovery. Individuals with insider knowledge or information relevant to the Hagens Berman investigation are also urged to contact the firm’s attorneys.

View our latest video summary of the allegations: youtu.be/90cf7_368dk

Class Period: Nov. 7, 2024 – Apr. 21, 2026
Lead Plaintiff Deadline: July 17, 2026
Visit:www.hbsslaw.com/investor-fraud/srad
Contact the Firm Now: [email protected]
                                         844-916-0895

What is the Sportradar Group AG (SRAD) Securities Class Action About?

The class action lawsuit alleges that Sportradar misrepresented and concealed that the company deliberately partnered with black-market unlicensed gambling operators to inflate its revenues, despite publicly touting strict legal and regulatory compliance and claiming that ethics and integrity were foundational to the company’s operations.

Investors’ confidence in Sportradar’s business practices, including its purported KYC and Code of Conduct, was shattered on April 22, 2026, when two prominent short seller firms published detailed investigative reports that directly contradicted Sportradar’s prior statements about compliance and corporate governance.

Muddy Waters Research conducted an undercover investigation, analyzed Sportradar’s website code, and interviewed 15 current and former company employees to reach its conclusion that “SRAD has actively aided and abetted illegal gambling across the world’s black and grey markets – not as an accident or an oversight, but as a business strategy.” The firm “estimate[d] that illegal operators today deliver approximately 20-40% of total revenues[]” to Sportradar. Muddy Waters said it “identified nearly 50 companies as current or recent SRAD clients and collaborators who are operating in illegal markets.”

For its part, Callisto examined hundreds of gambling platforms and reported that it found evidence that “over 270 individual platforms (more than a third of the 800 Sportradar claims to serve) are using Sportradar’s products or services, or explicitly claiming to do so, while operating illegally in regulated or prohibited gambling markets.” Callisto also said “[m]any of these operators have no license whatsoever[]” and “a senior former employee we spoke to estimated the exposure to unlicensed operators could be as high as 30-40% of Sportradar’s revenue.”

The market swiftly reacted, wiping out over $800 million of Sportradar’s market capitalization in a single day.

“Hagens Berman is investigating the lawsuit’s claims that Sportradar concealed an illegal business strategy from investors and may have booked revenues derived from unlawful gambling operations,” said Reed Kathrein, the Hagens Berman partner leading the firm’s Sportradar securities fraud investigation.

If you are a Sportradar (SRAD) investor who suffered substantial losses, or if you have information that could assist Hagens Berman’s investigation, contact the firm now.

For information about the Sportradar class action lawsuit and and answers to frequently asked questions, read more »

Whistleblowers: Persons with non-public information regarding Sportradar should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/srad-10-day-deadline-alert-hbss-investigates-sportradar-group-ag-srad-securities-class-action-claims-after-short-seller-reports-expose-alleged-illegal-gambling-ties-302820070.html

SOURCE Hagens Berman Sobol Shapiro LLP

SAN FRANCISCO, July 7, 2026 /PRNewswire/ — National shareholder rights firm Hagens Berman (HBSS) is actively investigating claims alleged against Veritone, Inc. (NASDAQ: VERI) and certain of its executives in a pending securities class action filed after the company admitted its previously issued financial statements were materially misstated.

SUBMIT YOUR VERI LOSSES TO HBSS

The firm’s investigation focuses on the suit’s claims that Veritone and its management violated the securities laws by intentionally misleading investors regarding the company’s financial performance through improper accounting practices during the period from October 14, 2025, to April 14, 2026.                                  

Allegations of Improper Accounting and Revenue Inflation:

The securities class action follows a series of disclosures in early 2026 that resulted in significant declines in Veritone’s share price. The core allegations, which emerged in a recently filed complaint against the company, claim that Veritone failed to disclose that it:

• Inaccurately recorded and/or misclassified certain revenue and costs. 
• Overstated its revenue, assets, accounts receivable, royalties, and other comprehensive income. 
• Maintained deficient internal controls over accounting and financial reporting. 
• Provided investors with positive statements regarding its business, operations, and prospects that lacked a reasonable basis.

Key Disclosures and Market Impact

• March 26, 2026: Veritone announced that it was “finalizing its accounting determination of certain revenue transactions,” causing shares to fall over 29% the following day.
• April 1, 2026: The company delayed its annual report filing due to accounting determination issues regarding barter revenue, leading to another stock decline. 
• April 14, 2026: Veritone formally disclosed that its unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2025, should no longer be relied upon, citing errors in software valuation and revenue misclassification, which drove the price of Veritone shares down further.

Hagens Berman’s Investigation

“Our investigation is focused on whether Veritone and its management intentionally misled investors about its financial performance using now-admitted improper accounting,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

Investor Rights and Court Deadlines

If you invested in Veritone securities during the Class Period (October 14, 2025 – April 14, 2026) and suffered financial losses, you may be eligible to serve as lead plaintiff in the ongoing litigation. The court-imposed deadline to move for appointment as lead plaintiff is July 20, 2026.

• 
  Report your losses
  
• Contact the Firm Now:
  
  [email protected]
  
• HBSS Investor Hotline: 844-916-0895
• Hagens Berman Veritone Site:
  www.hbsslaw.com/cases/veritone

View our latest video summary of the allegations: youtu.be/dflmz_R1g64

Whistleblowers: Persons with non-public information regarding Veritone should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/veri-investor-alert-hbss-probes-claims-alleged-against-veritone-inc-veri-in-pending-securities-class-action-regarding-alleged-accounting-irregularities-302820068.html

SOURCE Hagens Berman Sobol Shapiro LLP